{"id":"https://openalex.org/W1919558603","doi":"https://doi.org/10.1111/j.1365-2710.2012.01342.x","title":"Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes","display_name":"Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes","alternate_titles":[],"publication_year":2012,"publication_date":"2012-03-21","ids":{"openalex":"https://openalex.org/W1919558603","doi":"https://doi.org/10.1111/j.1365-2710.2012.01342.x","mag":"1919558603","pmid":"https://pubmed.ncbi.nlm.nih.gov/22436069"},"language":"en","primary_location":{"id":"doi:10.1111/j.1365-2710.2012.01342.x","doi":"https://doi.org/10.1111/j.1365-2710.2012.01342.x","is_oa":false,"landing_page_url":"https://doi.org/10.1111/j.1365-2710.2012.01342.x","pdf_url":null,"source":{"id":"https://openalex.org/S156693432","display_name":"Journal of Clinical Pharmacy and Therapeutics","issn_l":"0269-4727","issn":["0269-4727","1365-2710"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","jufo-1","norway-1","poland-70","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Pharmacy and Therapeutics","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W1919558603"],"child_works_count":0,"type":"review","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5090784160","display_name":"Susan A. Cornell","orcid":"https://orcid.org/0000-0002-9934-035X","observed_orcids":["https://orcid.org/0000-0002-9934-035X"]},"institutions":[{"id":"https://openalex.org/I128902783","display_name":"Midwestern University","ror":"https://ror.org/046yatd98","country_code":"US","type":"education","lineage":["https://openalex.org/I128902783"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"S. Cornell","raw_affiliation_strings":["Chicago College of Pharmacy, Midwestern University, Downers Grove, IL 60515, USA. scorne@midwestern.edu","Chicago College of Pharmacy, Midwestern University, Downers Grove, IL 60515, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Chicago College of Pharmacy, Midwestern University, Downers Grove, IL 60515, USA. scorne@midwestern.edu","institution_ids":["https://openalex.org/I128902783"]},{"raw_affiliation_string":"Chicago College of Pharmacy, Midwestern University, Downers Grove, IL 60515, USA","institution_ids":["https://openalex.org/I128902783"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5090784160"],"corresponding_institution_ids":["https://openalex.org/I128902783"],"apc_list":{"value":2700,"currency":"USD","value_usd":2700},"apc_paid":null,"fwci":0.7609,"has_fulltext":false,"cited_by_count":42,"citation_normalized_percentile":{"value":0.58652199,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":86,"max":99},"biblio":{"volume":"37","issue":"5","first_page":"510","last_page":"524"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10560","display_name":"Diabetes Management and Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12539","display_name":"Pharmacology and Obesity Treatment","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.949999988079071},{"id":"https://openalex.org/keywords/incretin-based-therapy","display_name":"incretin-based therapy","score":0.8550000190734863},{"id":"https://openalex.org/keywords/glp-1-receptor-agonists","display_name":"GLP-1 receptor agonists","score":0.9229999780654907},{"id":"https://openalex.org/keywords/dpp-4-inhibitors","display_name":"DPP-4 inhibitors","score":0.9980000257492065},{"id":"https://openalex.org/keywords/liraglutide","display_name":"liraglutide","score":0.7990000247955322},{"id":"https://openalex.org/keywords/exenatide","display_name":"exenatide","score":0.9700000286102295},{"id":"https://openalex.org/keywords/hba1c","display_name":"HbA1c","score":0.7559999823570251},{"id":"https://openalex.org/keywords/fasting-blood-glucose","display_name":"fasting blood glucose","score":0.9259999990463257},{"id":"https://openalex.org/keywords/postprandial-blood-glucose","display_name":"postprandial blood glucose","score":0.953000009059906},{"id":"https://openalex.org/keywords/weight-loss","display_name":"weight loss","score":0.875},{"id":"https://openalex.org/keywords/beta-cell-function","display_name":"beta-cell function","score":0.8579999804496765},{"id":"https://openalex.org/keywords/hypoglycemia","display_name":"hypoglycemia","score":0.8769999742507935},{"id":"https://openalex.org/keywords/drug-selection","display_name":"drug selection","score":0.7450000047683716},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.5329999923706055},{"id":"https://openalex.org/keywords/obesity","display_name":"obesity","score":0.5230000019073486},{"id":"https://openalex.org/keywords/hypertension","display_name":"hypertension","score":0.9380000233650208},{"id":"https://openalex.org/keywords/cardiovascular-risk","display_name":"cardiovascular risk","score":0.5759999752044678},{"id":"https://openalex.org/keywords/drug-safety","display_name":"drug safety","score":0.41200000047683716}],"concepts":[{"id":"https://openalex.org/C2780533449","wikidata":"https://www.wikidata.org/wiki/Q417762","display_name":"Exenatide","level":4,"score":0.9599742889404297},{"id":"https://openalex.org/C2778881409","wikidata":"https://www.wikidata.org/wiki/Q1420402","display_name":"Incretin","level":4,"score":0.943909764289856},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.894868791103363},{"id":"https://openalex.org/C2781308992","wikidata":"https://www.wikidata.org/wiki/Q2526479","display_name":"Liraglutide","level":4,"score":0.7466034889221191},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.7403149604797363},{"id":"https://openalex.org/C156490143","wikidata":"https://www.wikidata.org/wiki/Q412214","display_name":"Dipeptidyl peptidase-4","level":4,"score":0.5531885027885437},{"id":"https://openalex.org/C2776453732","wikidata":"https://www.wikidata.org/wiki/Q421042","display_name":"Vildagliptin","level":4,"score":0.5201212167739868},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.49969053268432617},{"id":"https://openalex.org/C185280430","wikidata":"https://www.wikidata.org/wiki/Q14909910","display_name":"Glucagon-like peptide 1 receptor","level":4,"score":0.4871477782726288},{"id":"https://openalex.org/C2779284873","wikidata":"https://www.wikidata.org/wiki/Q419832","display_name":"Sitagliptin","level":4,"score":0.48129335045814514},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.4808714985847473},{"id":"https://openalex.org/C500440147","wikidata":"https://www.wikidata.org/wiki/Q701216","display_name":"Pharmacotherapy","level":2,"score":0.47091078758239746},{"id":"https://openalex.org/C2776442814","wikidata":"https://www.wikidata.org/wiki/Q6659956","display_name":"Lixisenatide","level":5,"score":0.4650360941886902},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.4575064182281494},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.42051267623901367},{"id":"https://openalex.org/C2776398474","wikidata":"https://www.wikidata.org/wiki/Q424611","display_name":"Glucagon-like peptide-1","level":4,"score":0.42023220658302307},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.3266887664794922},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.18174025416374207},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.11654356122016907}],"mesh":[{"descriptor_ui":"D000067757","descriptor_name":"Glucagon-Like Peptide-1 Receptor","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001786","descriptor_name":"Blood Glucose","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000097","qualifier_name":"blood","is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D016032","descriptor_name":"Randomized Controlled Trials as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018027","descriptor_name":"Receptors, Glucagon","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D018027","descriptor_name":"Receptors, Glucagon","qualifier_ui":"Q000819","qualifier_name":"agonists","is_major_topic":true},{"descriptor_ui":"D054795","descriptor_name":"Incretins","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D054795","descriptor_name":"Incretins","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D054873","descriptor_name":"Dipeptidyl-Peptidase IV Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1111/j.1365-2710.2012.01342.x","doi":"https://doi.org/10.1111/j.1365-2710.2012.01342.x","is_oa":false,"landing_page_url":"https://doi.org/10.1111/j.1365-2710.2012.01342.x","pdf_url":null,"source":{"id":"https://openalex.org/S156693432","display_name":"Journal of Clinical Pharmacy and Therapeutics","issn_l":"0269-4727","issn":["0269-4727","1365-2710"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","jufo-1","norway-1","poland-70","russia-white-list-3","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Pharmacy and Therapeutics","raw_type":"journal-article"},{"id":"pmid:22436069","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/22436069","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of clinical pharmacy and therapeutics","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Systematic Review","id":"https://openalex.org/study-designs/systematic-review"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320322436","display_name":"Novo Nordisk","ror":"https://ror.org/0435rc536"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":90,"referenced_works":["https://openalex.org/W1518543897","https://openalex.org/W1532170875","https://openalex.org/W1547073044","https://openalex.org/W1559082056","https://openalex.org/W1755903692","https://openalex.org/W1966469183","https://openalex.org/W1970125713","https://openalex.org/W1972308825","https://openalex.org/W1975591028","https://openalex.org/W1977102586","https://openalex.org/W1981183973","https://openalex.org/W1981555824","https://openalex.org/W1984805407","https://openalex.org/W1984805650","https://openalex.org/W1986331352","https://openalex.org/W1992868203","https://openalex.org/W1994743271","https://openalex.org/W2004409542","https://openalex.org/W2005230361","https://openalex.org/W2026348270","https://openalex.org/W2028092672","https://openalex.org/W2033665483","https://openalex.org/W2038953694","https://openalex.org/W2043900831","https://openalex.org/W2045063167","https://openalex.org/W2045321591","https://openalex.org/W2045970464","https://openalex.org/W2047041946","https://openalex.org/W2048728983","https://openalex.org/W2050826565","https://openalex.org/W2057913111","https://openalex.org/W2060124483","https://openalex.org/W2061691264","https://openalex.org/W2069661907","https://openalex.org/W2071835038","https://openalex.org/W2074142099","https://openalex.org/W2078090288","https://openalex.org/W2084744936","https://openalex.org/W2084948079","https://openalex.org/W2087025850","https://openalex.org/W2090920461","https://openalex.org/W2098459806","https://openalex.org/W2101246901","https://openalex.org/W2102400698","https://openalex.org/W2102511839","https://openalex.org/W2103058881","https://openalex.org/W2103266155","https://openalex.org/W2103525547","https://openalex.org/W2105926302","https://openalex.org/W2107949845","https://openalex.org/W2108646121","https://openalex.org/W2109728760","https://openalex.org/W2111901007","https://openalex.org/W2112981414","https://openalex.org/W2113367996","https://openalex.org/W2114927834","https://openalex.org/W2116492775","https://openalex.org/W2116969055","https://openalex.org/W2118186702","https://openalex.org/W2118710260","https://openalex.org/W2118762421","https://openalex.org/W2118889627","https://openalex.org/W2126065052","https://openalex.org/W2128648250","https://openalex.org/W2137352234","https://openalex.org/W2138077952","https://openalex.org/W2138290933","https://openalex.org/W2139485303","https://openalex.org/W2140240975","https://openalex.org/W2140480989","https://openalex.org/W2140952918","https://openalex.org/W2140978079","https://openalex.org/W2142400535","https://openalex.org/W2143847100","https://openalex.org/W2145266416","https://openalex.org/W2146901298","https://openalex.org/W2152984355","https://openalex.org/W2157869836","https://openalex.org/W2158727328","https://openalex.org/W2158778171","https://openalex.org/W2159198773","https://openalex.org/W2159205789","https://openalex.org/W2160001758","https://openalex.org/W2160511051","https://openalex.org/W2164416879","https://openalex.org/W2169760435","https://openalex.org/W2170606300","https://openalex.org/W2191569664","https://openalex.org/W2344620176","https://openalex.org/W2607126146"],"related_works":["https://openalex.org/W2075070224","https://openalex.org/W2091480327","https://openalex.org/W2092287139","https://openalex.org/W2514777534","https://openalex.org/W2045271826","https://openalex.org/W2098083442","https://openalex.org/W183293552","https://openalex.org/W1545603700","https://openalex.org/W2130143203","https://openalex.org/W1955912841"],"abstract_inverted_index":{"WHAT":[0,292],"IS":[1,293],"KNOWN":[2],"AND":[3,126,295],"OBJECTIVE:":[4],"Incretin-based":[5],"glucagon-like":[6],"peptide-1":[7,129],"receptor":[8,130],"agonists":[9,131],"(GLP-1":[10],"RAs)":[11],"and":[12,57,97,106,112,148,151,165,268,278,290,303,306,320,324,335],"dipeptidyl":[13],"peptidase-4":[14],"(DPP-4)":[15],"inhibitor":[16],"therapies":[17,31,94,118,258,334],"provide":[18],"glycaemic":[19,111,305],"control":[20],"with":[21,25,34,73,206,283],"reduced":[22],"risks":[23],"associated":[24,282],"weight":[26,153,250],"gain":[27],"or":[28,210,230,242],"hypoglycaemia.":[29],"Incretin":[30],"are":[32,132,203,228,240],"compared":[33],"their":[35,59,140,176],"mechanisms":[36,300],"of":[37,68,115,139,175,265,271,279,301,344],"action,":[38],"effects":[39,114,179,202],"on":[40,180],"haemoglobin":[41],"A(1C)":[42],"(HbA(1C)),":[43],"fasting":[44],"plasma":[45],"glucose":[46,49],"(FPG),":[47],"post-prandial":[48],"(PPG),":[50],"body":[51],"weight,":[52],"\u03b2-cell":[53,266],"function,":[54],"cardiovascular":[55],"biomarkers":[56],"in":[58,65,99,143,222,299,304,341],"safety":[60],"profiles":[61],"to":[62,121,232,255],"aid":[63,340],"clinicians":[64],"the":[66,100,244,316,342,345],"selection":[67,343],"individualized":[69,350],"pharmacotherapy":[70],"for":[71,80,213,349],"patients":[72,209,217,226],"type":[74,275,284],"2":[75,276,285],"diabetes.":[76],"METHODS:":[77],"Relevant":[78],"articles":[79],"a":[81,157,187,197],"systematic":[82],"review":[83],"were":[84,95,123],"identified":[85,96],"through":[86],"PubMed.":[87],"Randomized,":[88],"head-to-head":[89],"comparison":[90],"studies":[91,109],"among":[92,311,332],"incretin":[93,117,312,333,347],"included":[98],"review.":[101],"Additionally,":[102],"randomized,":[103],"controlled":[104],"monotherapy":[105,158],"combination":[107],"therapy":[108],"examining":[110],"extraglycaemic":[113],"individual":[116],"from":[119,249],"2007":[120],"2011":[122],"reviewed.":[124],"RESULTS":[125],"DISCUSSION:":[127],"Glucagon-like":[128],"generally":[133],"preferred":[134,170],"over":[135],"DPP-4":[136,214,325],"inhibitors":[137,215],"because":[138,174],"greater":[141,152],"effectiveness":[142],"reducing":[144],"HbA(1C)":[145,173,185],",":[146,186],"FPG":[147],"PPG":[149],"excursions,":[150],"loss":[154],"potentiation.":[155],"As":[156],"option,":[159],"longer-acting":[160],"GLP-1":[161,189,238,317,322],"RAs,":[162],"including":[163],"liraglutide":[164],"exenatide":[166,193],"once-weekly,":[167],"may":[168,195],"be":[169,196],"at":[171],"higher":[172],"more":[177,204],"pronounced":[178,205],"FPG.":[181],"At":[182],"lower/near":[183],"normal":[184],"short-acting":[188],"RA,":[190],"such":[191,287],"as":[192,200,288],"twice-daily,":[194],"better":[198],"choice":[199],"its":[201],"PPG.":[207],"Ideal":[208],"patient":[211,245,337],"situations":[212],"include":[216,259],"who":[218,227],"need":[219],"minimal":[220,260],"reduction":[221],"HbA(1C,)":[223],"elderly":[224],"patients,":[225],"unwilling":[229],"unable":[231],"take":[233],"an":[234],"injectable":[235],"agent,":[236],"when":[237,243],"RAs":[239,323],"contraindicated":[241],"will":[246,339],"not":[247],"benefit":[248],"loss.":[251],"Treatment":[252],"benefits":[253],"common":[254],"all":[256],"incretin-based":[257],"hypoglycaemia":[261],"risk,":[262],"potential":[263],"preservation":[264],"function":[267],"effective":[269],"targeting":[270],"multiple":[272],"organs":[273],"underlying":[274],"diabetes":[277],"comorbidities":[280],"commonly":[281],"diabetes,":[286],"obesity":[289],"hypertension.":[291],"NEW":[294],"CONCLUSION:":[296],"Key":[297],"differences":[298,331],"action":[302],"extra-glycaemic":[307],"treatment":[308],"outcomes":[309],"exist":[310],"therapies,":[313],"both":[314],"within":[315],"RA":[318],"class,":[319],"between":[321],"inhibitors.":[326],"Clinical":[327],"judgment":[328],"acknowledging":[329],"important":[330],"treatment-related":[336],"characteristics":[338],"appropriate":[346],"agent":[348],"pharmacotherapy.":[351]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W1919558603","counts_by_year":[{"year":2024,"cited_by_count":2},{"year":2022,"cited_by_count":1},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":6},{"year":2017,"cited_by_count":8},{"year":2015,"cited_by_count":3},{"year":2014,"cited_by_count":9},{"year":2013,"cited_by_count":8},{"year":2012,"cited_by_count":1}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
